STC Life Co., Ltd. Successfully Treats Patients With Parkinson's Disease at Stem Cell Research and Treatment Center
February 19, 2014 - SEOUL, SOUTH KOREA
Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Director: WON JU JUNG) successfully completed mesenchymal stem cell therapy for the patients with Parkinson’s disease, a chronic progressive degenerative disease in nervous system.
Parkinson’s disease is caused when dopamine nerve cells distributed in substance nigra become gradually extinct. It is a chronic progressive degenerative disease characteristically showing quiver, stiffness, bradykinesia and postural instability. General medicine treatment has no effect on Parkinson’s disease and there are no other treatments for it.
97.7 B&H Clinic (Representative Director: WON JU JUNG, www.977bnh.com) administered stem cell into vein of the patients with Parkinson’s disease 3 times every 2 weeks. Mesenchymal stem cell, one of the adult stem cells, is used a lot for neogenesis, and stem cell research institute (Director: SANG YEON LEE) of STC Life Co., Ltd. used stem cells separated from umbilical cord of fetus.
The patients who got stem cell therapy showed remarkable reduction of the symptoms such as lalopathy and paralysis of arms and legs and also showed satisfactory progress to be able to do light exercise. Furthermore, their linguistic ability, visual function and memory have increased and have not shown remarkable deterioration in cognitive function.
According to the result, Chairman KYE HO LEE of STC Life (www.stclife.com) revealed his strong ambitions to push harder to attract overseas patients and domestic patients with hard-to-cure diseases in the future.
It is proven that Mesenchymal stem cell therapy can reduce the symptoms with no adverse effects.
CONTACTS : Media contact: STC Life Co., Ltd Oh minsun, +82 2 3438 0653 Director firstname.lastname@example.org
Source: Business Wire India